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Epidermal growth factor receptor (EGFR) is known to
be critically involved in tissue development and
homeostasis as well as in the pathogenesis of
cancer. Here we showed that Foxp3+ regulatory T
(Treg) cells express EGFR under inflammatory condi-
tions. Stimulation with the EGF-like growth factor
Amphiregulin (AREG) markedly enhanced Treg cell
function in vitro, and in a colitis and tumor vaccina-
tion model we showed that AREG was critical for
efficient Treg cell function in vivo. In addition, mast
cell-derived AREG fully restored optimal Treg cell
function. Thesefindings reveal EGFRasacomponent
in the regulation of local immune responses and
establish a link between mast cells and Treg cells.
Targeting of this immune regulatory mechanism
may contribute to the therapeutic successes of
EGFR-targeting treatments in cancer patients.
INTRODUCTION
Stimulation of the intrinsic tyrosine kinase activity of the
epidermal growth factor receptor (EGFR) induces a complex
cascade of phosphorylation and activation events that deter-
mine cell-fate decisions, such as proliferation or differentiation,
and the development of tumors (Schlessinger, 2000; Avraham
and Yarden, 2011). The EGFR is well established to be ubiqui-
tously expressed but, in general, is thought to be absent on
the hematopoietic cell linage. This assumption has ignored
sporadic demonstrations of EGFR expression on leukocyte pop-
ulations, such as monocytes (Chan et al., 2009) or plasma cells
(Mahtouk et al., 2005). In addition to EGFR, its ligands have
also been shown to be produced not only by epithelial cells
but also by activated leukocyte and lymphocyte populations.
For example, the EGF-like growth factor Amphiregulin (AREG)
is expressed by activated Th2 cells (Zaiss et al., 2006), mast cells
(Wang et al., 2005; Okumura et al., 2005), eosinophils (Matsu-
moto et al., 2009), and basophils (Qi et al., 2010). These datasuggest that the EGFR signaling pathway could play a more
substantial role within the immune system than so far
appreciated.
Hints for such an assumption can also be found from the
widespread use of EGFR-targeted treatments in cancer patients.
Targeting the EGFR has become an established approach in
tumor treatment and such treatments improve the overall and
the progression-free survival of patients suffering from different
types of cancer, such as colorectal (Cunningham et al., 2004)
and non-small-cell lung cancer (NSCLC) (Bonner et al., 2006).
The observed clinical successes of this treatment remain poorly
understood but are assumed to be predominantly mediated by
interference with survival and growth signals needed by the
tumor. This concept is supported by a number of findings,
such as the demonstration of tumor adaption within a patient
in response to treatment (Montagut et al., 2012), suggesting
strong evolutionary pressure mediated by treatment on the
tumor. Nevertheless, other studies indicate that a substantial
part of the clinical responses observed after EGFR targeting
treatments may be mediated not only by direct effects on the
tumor but also by treatment-induced immune responses (Ferris
et al., 2010). For example, Garrido et al. (2007) demonstrated
in a Lewis lung cell tumor model that the effect of an EGFR
blocking antibody treatment was virtually entirely mediated by
treatment-induced T cell responses. Such involvement of treat-
ment-induced immune responses may also explain a number
of somewhat enigmatic clinical reports, such as objective clinical
responses to EGFR-targeted treatments from patients with
tumors lacking detectable EGFR expression (Chung et al.,
2005). Most interestingly, it has been reported that the expres-
sion of AREG constitutes the best known predictor for a low
therapy efficacy in cancer patients with a tumor expressing
a nonmutated form of K-Ras (Tinhofer et al., 2011; Jacobs
et al., 2009; Khambata-Ford et al., 2007; Ishikawa et al., 2005).
AREG is known to be a type II cytokine (Zaiss et al., 2006), for
which it is established that one of their main function is the
control of inflammation (Chen et al., 2012). In light of these find-
ings, we wanted to determine whether AREG may contribute to
the regulation of immune responses. This study showed that
regulatory T (Treg) cells expressed EGFR under inflammatory
conditions and that AREG was of pivotal importance to ensureImmunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc. 275
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Figure 1. BM Chimeric WT Mice Reconsti-
tuted with Areg–/– BM Develop Dermatitis
(A and B) BL6-SJL (CD45.1) or Areg/ mice were
irradiated with 10 Gy X rays and reconstituted with
107 BM cells derived from BL6-SJL or Areg/
mice. Incidence of dermatitis of recipient mice
6 weeks after BM transfer is shown (n = 4 mice per
group, bars represent means + SEM).
(C) Lymphocytes derived from mesenteric lymph
nodes of WT or Areg/mice were stained for CD4
and intracellular for FoxP3; frequency of FoxP3-
expressing cells is shown (n = 4 mice per group,
bars represent means + SEM).
For additional information, see Figure S1.
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Immune Regulatory Effect of EGFR Signalingoptimal Treg cell-mediated immune regulation. Thus, our data
reveal a mechanism by which Treg cell function is regulated at
the site of inflammation.
RESULTS
Amphiregulin Gene-Deficient Mice Display Immune
Regulatory Dysfunction
Wepreviously identified the EGF-like growth factor Amphiregulin
(AREG) as a type II cytokine (Zaiss et al., 2006). While character-
izing AREG gene-deficient (Areg/) mice, we noticed an
immune regulatory dysfunction in this mouse strain. This was
evident, for example, from enhanced frequencies of antigen
(Ag)-specific CD4+ T cells in Areg/ compared with wild-type
(WT) C57BL/6 mice after Listeria monocytogenes infection
(data not shown) and from the development of dermatitis after
bone marrow (BM) transplantation of Areg/ BM into WT recip-
ient C57BL/6 mice (Figures 1A and 1B). Because FoxP3-ex-
pressing Treg cells are of crucial importance for both dampening
CD4+ T cell responses and immune tolerization after BM trans-
plantation (Cobbold et al., 2006), we postulated that Treg cell
function could be impaired in the absence of AREG. Flow cytom-
etry analyses, however, showed similar frequencies of FoxP3-
expressing Treg cells in the secondary lymphoid organs of
Areg/ and WT mice (Figure 1C). Also in the skin-draining,
inguinal LN of BM chimeric C57BL/6 WT mice that had received276 Immunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc.Areg/ BM, normal frequencies of
FoxP3-expressing Treg cells were de-
tected (Figure S1A available online).
These data indicate that neither insuffi-
cient numbers nor lack of homing of
Treg cells to the site of inflammation could
explain the lack of immune regulation
observed in Areg/ mice.
Regulatory T Cells Express the
EGFR
To determine whether AREG might have
a direct effect on Treg cells, wemeasured
EGFR expression on T cells ex vivo. To
this end, we sorted Treg cells from
FoxP3-GFP transgenic mice based on
GFP expression, as well as Treg cells
derived from peripheral blood mononu-clear cells (PBMCs) of healthy donors based on high expression
of CD25 and the presence or absence of CD127. Analysis by
quantitative RT-PCR (qRT-PCR) showed clearly detectable
amounts of EGFRmRNA in Treg cells derived from either species
(Figures 2A–2C). In human PBMCs, very low EGFR mRNA
expression was detectable also in conventional CD4+ T cells,
but not in CD8+ T cells (Figure 2B).
To verify EGFR expression on Treg cells by flow cytometry
analysis, we used a biotinylated nanobody specific for a shared
region of the mouse and human EGFR (Figure S6). About 15% of
the FoxP3- and Helios-expressing CD4+ T cells in the peripheral
blood of healthy volunteers expressed the EGFR (Figure 2D, for
gating strategies see Figure S2A) and very low amounts of EGFR
were detectable on FoxP3-expressing CD4+ T cells in the spleen
of healthy mice (data not shown). B16 melanoma-residential
Treg cells, however, expressed well detectable amounts of the
EGFR (Figure 2E, for gating strategies see Figure S2B). The
staining was specific and absent on FoxP3-expressing CD4+
T cells derived from B16 melanoma of Egfrflox/flox 3 Cd4-cre
mice (Figure 2E). Because in humans almost all EGFR-express-
ing Treg cells were FoxP3hi and CD45RA (Figure S2C),
a subtype of Treg cells that Sakaguchi and colleagues described
as activated Treg cells (Miyara et al., 2009), and because human
Treg cells gained EGFR expression upon in vitro activation (data
not shown), we concluded that Treg cells express the EGFR
upon activation.
AD E
CB Figure 2. Treg Cells Express EGFR
(A and B) T cells from the blood of healthy volun-
teers were sorted by flow cytometry based on CD4
and CD8 expression. Effector T cells and Treg
cells were further separated based on nonover-
lapping expression markers, i.e., CD127hi versus
CD127lo and CD25lo versus CD25hi, respectively.
EGFR expression was determined by quantitative
RT-PCR. Absolute expression in comparison to
b2 m expression (A) and relative EGFR expression
of different T cell populations to each other (B). n =
3 volunteers per group, bars represent means +
SEM. ND, nondetectible (no signal for EGFR).
(C) Tregcellsderived fromthespleenofFoxP3-GFP
mice were sorted by flow cytometry based on GFP
expression. EGFR mRNA expression was deter-
mined by quantitative RT-PCR (experiment per-
formed in triplicate, bar represents means ± SEM).
(D) PBMCs of healthy volunteers were blocked
with an excess of unspecific nanobodies and then
stained for CD4 and for EGFR via an EGFR-
specific biotinylated nanobody. Thereafter, cells
were stained intracellularly for Helios and FoxP3
and SA-PE. Black line shows EGFR staining; filled
line represents background SA-PE-only staining.
(E) EGFR expression on tumor-infiltrating Treg
cells derived from B16 melanoma of WT C57BL/6
orEgfrflox/flox3Cd4-cremicewas analyzed by flow
cytometry. Cells were stained for CD4, EGFR, and
FoxP3. Full lines show the staining of Treg cells
derived from WT mice, filled lines the staining of
Treg cells derived fromEgfrflox/flox3Cd4-cremice.
For additional information, see Figure S2.
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Immune Regulatory Effect of EGFR SignalingAmphiregulin Enhances Regulatory T Cell Function
The EGFR and the T cell receptor (TCR) share a common signal
transduction pathway, the ERK-MAP-kinase module, and AREG
treatment substantially increased ERK activation in differenti-
ated induced Treg cells (Figure 3A). In contrast to in effector
T cells, where upon TCR engagement the MAP kinase pathway
in a binary manner is briefly activated and then rapidly turned
off (Altan-Bonnet and Germain, 2005), this pathway in Treg cells
is activated for an extended period of time (Tsang et al., 2006).
This situation closely correlated with the MAP kinase signal
transduction pathway downstream of the EGFR. Most EGFR
ligands, such as EGF or TGF-a, induce a strong but transient
signal. Such a signal initiates ubiquitination via the E3-ligase
Clb, which then induces rapid internalization and degradation
of the EGFR and thus a transient desensitization. AREG ligation
on the other hand induces a sustained, tonic signal through the
MAP kinase signal transduction pathway, which does not induce
internalization and degradation of the EGFR (Stern et al., 2008).
Thus, we hypothesized that an AREG-induced signal may
support and sustain MAP kinase activation in Treg cells, thereby
enhancing their regulatory function.
To address this hypothesis, we determined the effect of AREG
on modulating Treg cell function in in vitro suppression assays.
As shown in Figures 3B and S3A, the presence of AREG during
the assay significantly enhanced the suppressive capacity of
Treg cells. Importantly, AREG had no influence on the overall
proliferation or survival of Treg cells and did not directly influence
the proliferation of effector cells (Figures S3B and S3C). As
a control for the specificity of AREG, we performed in vitrosuppression assays in the presence of the EGFR-specific tyro-
sine kinase inhibitor Gefitinib, which entirely eliminated the
AREG-mediated effect (Figure 3C).
The effect of AREG on the suppressive activity of Treg cells
became more pronounced the more the activating anti-CD3ε
was diluted (Figure 3D). Although the dilution of the antibody
had no appreciable direct effect on the proliferation of the
effector T cells (data not shown), the suppressive capacity of
Treg cells substantially declined in the absence but not in the
presence of AREG.
Based on these data we concluded that AREG directly
enhances the suppressive capacity of Treg cells in vitro, most
probably by enhancing and sustaining the TCR-induced signal
through the MAP kinase signaling pathway.
Amphiregulin Is Essential for Efficient Regulatory T Cell
Function In Vivo
To determine the physiological relevance of AREG expression on
Treg cell function in vivo, we tested the suppressive capacity of
Treg cells in a T cell transfer colitis model, the gold standard to
determine Treg cell function in vivo (Powrie et al., 1994). To
this end, we transferred naive CD4+ T cells in the presence or
absence of Treg cells into lymphopenic RAG1-deficient
(Rag1/) or Areg/Rag1/ mice. Colitis development was
determined 6 weeks after transfer according to a histological
score established by Berg et al. (1996). As shown in Figure 4A,
transfer of a fixed number of naive CD4+ T cells together
with increasing amounts of Treg cells into either Rag1/ or
Areg/Rag1/ mice decreased the severity of disease in aImmunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc. 277
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Figure 3. Amphiregulin Enhances the Suppressive Capacity of EGFR-Expressing Treg Cells In Vitro
(A) iTreg cells were differentiated form umbilical cord bloodCD4+ T cells in the presence of TGF-b. After 5 days of differentiation, 0.53 107 cells were either treated
with 100 ng/ml AREG or left untreated and ERK activation determined by protein blot with p-ERK-specific antiserum.
(B and C) PBMCs derived from healthy volunteers were stimulated with membrane-bound anti-CD3 and CD25+CD127CD4+ Treg cells were added to suppress
proliferation of CFSE-labeled CD4+ T cells in the presence or absence of at least 100 ng/ml recombinant AREG (B) and in the presence or absence of 100 ng/ml
Gefitinib (C). Proliferation was defined as the percentage of cells that had undergone at least one division. Experiment performed in triplicate; bars represent
means + SEM.
(D) Mouse FoxP3-GFP CD4+ T cells were cultured for 4 days together with CFSE-labeled CD45.1-expressing splenocytes at a ratio of 1:4 in the presence or
absence of 100 ng/ml recombinant AREG. T cells were activated with different amounts of soluble anti-CD3, and CFSE dilution within the CD45.1-expressing
CD8+ T cell population was analyzed by flow cytometry. Proliferation was defined as the percentage of cells that had undergone at least one division. Triangles,
inhibition in the presence of AREG; squares, inhibition in the absence of AREG. Experiments performed in triplicate; points are means ± SEM.
For additional information, see Figure S3.
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Immune Regulatory Effect of EGFR Signalingdose-dependent manner in both Rag1/ and Areg/Rag1/
mice. However, transferred Treg cells were significantly less
suppressive inAreg/Rag1/ than inRag1/mice (Figure 4A).
Because the total number of Treg cells as well as the frequency
of Treg cells within the T cell population recovered from the
mesenteric lymph nodes and spleen correlated more with
the state of inflammation than with the genetic background of
the animal (data not shown), we concluded that also in vivo
AREG does not influence the proliferation or survival of trans-
ferred T cells but directly enhances the suppressive capacity
of Treg cells.
To verify that the AREG-mediated effect was directly mediated
via Treg cell-expressed EGFR, we crossed Egfrflox/flox mice onto
a Cd4-cre background and transferred sorted Treg cells based
on CD25 expression derived from WT and from Egfrflox/flox 3
Cd4-cre mice into Rag1/ mice. Both CD25-expressing popu-
lations contained similar frequencies of FoxP3-expressing cells
(Figure S4G); however, as shown in Figure 4B, EGFR gene-defi-
cient Treg cells were significantly less capable of suppressing
the development of colitis than Treg cells derived from WT
mice. EGFR gene-deficient naive CD4+ T cells, however, were
fully able to induce colitis upon transfer into Rag1/ mice and
Treg cells derived from WT mice could efficiently suppress their
effector function (Figure 4C). These data show that EGFR-medi-
ated signaling does not affect the functionality or the regulation
of effector T cells, although at the same time Treg cells are
directly dependent on AREG-induced signals for optimal func-
tioning in vivo.
Amphiregulin Protects B16 Tumors against Tumor
Immunization
EGFR-targeting treatment methodologies are well established in
the clinic for the treatment of tumors. Specific side effects, such
as skin rashes, have been observed after treatment that could
suggest treatment-associated immune dysregulation. At the
same time, has it been shown that Treg cells can constitute an278 Immunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc.important escape mechanism by which tumors protect them-
selves against tumor-specific immune responses (Zou, 2006).
To test the hypothesis that the EGFR-targeting treatments could
affect Treg cell function, we performed tumor immunization
experiments in the presence and absence of an EGFR-blocking
antibody and Gefitinib, an EGFR-specific tyrosine kinase inhib-
itor (TKI). We used the B16 melanoma model, for which the
pivotal role of Treg cells in the generation of a tumor-intrinsic
immuno-suppressive environment is well established (Sutmuller
et al., 2001). So can tumor immunization-induced rejection of
transplanted B16-F10 tumors be achieved in WT C57BL/6
mice, if Treg cells are depleted prior to tumor transfer and
immunization (Sutmuller et al., 2001). Moreover, B16-F10 tumors
lack EGFR expression (Figure 5A). To test the relevance of
AREG-EGFR interaction in Treg cell functioning in this tumor
model, we immunized B16 transplanted mice with TRP2180-188
tumor epitope-pulsed in vitro differentiated bone marrow-
derived dendritic cells (BM-DCs) 5 and 7 days after tumor
transplantation. Concomitant to immunization, mice were
treated with EGFR-blocking nanobodies every second day or,
as a control (Matsushita et al., 2008), once with a low dose of
cyclophosphamide (Figure 5B). As described before (Sutmuller
et al., 2001; Matsushita et al., 2008), immunization alone had
no effect on tumor growth in C57BL/6 mice. Also, nanobody or
cyclosphosphamide treatment each by itself exerted no
substantial influence on tumor growth. The combination of
immunization with nanobody treatment, however, significantly
enhanced the efficacy of the peptide-pulsed BM-DC immuniza-
tion (Figure 5B). A similar enhanced efficacy of peptide-pulsed
BM-DC immunization was obtained after concomitant treatment
with the EGFR-specific tyrosine kinase inhibitor Gefitinib (Fig-
ure 5C), although slightly less pronounced than observed by
EGFR-blocking nanobody treatment. This slightly lower efficacy
is explained most probably by the short serum half-life of Gefiti-
nib of only approximately 6 hr, because of rapid excretion
through the kidney.
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Figure 4. Amphiregulin Enhances Treg Cell Function In Vivo
(A) Rag1/ (light bars) or Areg/Rag1/ (dark bars) mice received 400,000
flow cytometry-sorted naive CD4+ T cells together with increasing numbers of
FoxP-GFP-expressing Treg cells.
(B) Rag1/ mice received 400,000 naive CD4+ T cells together with 200,000
CD25+CD4+ T cells derived from either WT (light bar) or Egfrflox/flox 3 Cd4-cre
(dark bar) mice.
(C) Rag1/ mice received 400,000 naive CD4+ T cells derived from
Egfrflox/flox3Cd4-cremice in the presence or absence of 200,000 CD25+CD4+
T cells derived from WT mice.
Development of colitis wasmeasured 6 weeks later by histological score. Bars
represent means + SEM; results for individual mice are shown as circles. For
additional information and representative H&E staining of tissue samples
derived from the different mouse groups, see Figure S4.
Immunity
Immune Regulatory Effect of EGFR SignalingTaken together, our data show that EGFR-targeted treatments
can facilitate the rejection of a transplanted tumor that does not
express the EGFR, when applied concomitant to CD8+ T cell-
inducing antitumor immunization. These data indicate that
EGFR-mediated signals are of critical importance for Treg cell-
mediated establishment of a tumor-intrinsic immune-suppres-
sive environment.
To establish that the observed effects of EGFR-blocking
treatment indeed are AREG dependent and mediated via Treg
cell-expressed EGFR, we transferred B16-F10 melanoma cells
into WT C57BL/6, Areg/, or Egfrflox/flox 3 Cd4-cre mice andimmunized them with TRP2180-188 tumor epitope-pulsed BM-
DCs 5 and 7 days after tumor transplantation. B16 tumors
grew with similar characteristics in the different mouse strains
(Figures 5D and 5E) (although consistently somewhat faster in
AREG-deficient than in WT mice, as shown in Figure 5D);
however, unlike WT mice, Areg/ (Figure 5F) and Egfrflox/flox 3
Cd4-cre (Figure 5G) mice efficiently rejected transplanted B16-
F10 tumors upon immunization. Because BM-DC immunization
induced similar anti-TRP2180-188-specific immune responses in
the different mouse strains (data not shown) and we were not
able to detect EGFR expression in CD8+ T cells (Figure 2B), we
concluded that AREG-mediated enhancement of Treg cell func-
tion is of critical importance for the establishment of a tumor-
intrinsic immune-suppressive environment in B16 tumors that
prevents successful tumor rejection upon immunization in mice.
Mast Cell-Derived Amphiregulin Enhances Regulatory
T Cell Function
Next we investigated the physiologically relevant source of
AREG that enhances Treg cell function in vivo. Because Treg
cells and mast cells have been shown to cooperate with each
other (Lu et al., 2006; Hershko et al., 2011) and AREG has
been shown to be the single most upregulated growth factor
uponmast cell activation (Figure S5;Wang et al., 2005; Okumura
et al., 2005), we tested whether mast cells could be a source of
AREG in our models. To this end, we used mast cell-deficient
c-kitw-sh/w-sh mice (Grimbaldeston et al., 2005), which were re-
constituted with in vitro differentiated BM-derived mast cells
(BM-MCs) prior to B16 transplantation and DC immunization.
As shown in Figure 6A, c-kitw-sh/w-sh control mice that did not
receive in vitro differentiated BM-MCs or mice that had been re-
constituted with BM-MCs differentiated from BM from Areg/
mice efficiently controlled tumor growth after peptide-specific
immunization. In contrast, immunized mice reconstituted with
BM-MCs differentiated from BM derived from WT C57BL/6
mice failed to control B16 growth. Because tumor growth was
similar in all unimmunized c-kitw-sh/w-shmouse groups (Figure 6B)
and similar numbers of mast cells were detected in the peritu-
moral region surrounding blood vessels (Figure 6C) in all recon-
stituted c-kitw-sh/w-sh mice, these data indicate that in the
absence of AREG-expressing mast cells, Treg cell function
was impaired.
Experiments performed in the T cell transfer-induced colitis
model (Figures 6D and 6E) and the BM transfer-induced derma-
titis model (Figure S1B) confirmed the critical role of mast cell-
derived AREG in enhancing Treg cell function. Colitis scores in
c-kitw-sh/w-shRAG1/ mice that had been reconstituted with
BM-MCs differentiated from BM of WT mice prior to transfer
were 6 weeks after cotransfer of naive CD4+ T cells and Treg
cells significantly lower than in mice that had not received
BM-MCs or had been reconstituted with BM-MCs differentiated
from BM of Areg/ mice (Figure 6D). Transfer of naive
CD4+ T cells only led to similar severe forms of colitis in all
c-kitw-sh/w-shRAG1/ mouse groups (Figure 6E), indicating that
neither mast cells nor mast cell-derived AREG were necessary
for the functioning or differentiation of colitogenic effector
T cells. Also, cotransfer of BM-MCs differentiated from BM
derived from WT C57BL/6 mice, but not of BM-MCs differenti-
ated from BM derived from Areg/ mice, prevented theImmunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc. 279
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Figure 5. AREG Is of Critical Importance for
the Efficient Suppression of Antitumor
Immune Responses
(A) mRNA from B16-F10 tumor cells and control
lung tissue was purified and quantitative RT-PCR
was performed. Bar is mean of ratio GAPDH:EGFR
expression + SEM. ND, nondetectable (no signal
for EGFR).
(B and C) 13 104 B16-F10 cells were injected s.c.
into the left flank of WT C57BL/6 mice. On days 5
and 7 after tumor cell transfer, mice were immu-
nized with BM-DCs loaded with an immunogenic
B16 melanoma epitope (TRP2180-188) or left
unimmunized. One mouse group received in
addition 300 mg purified EGFR-blocking nano-
bodies (B) or 200 mg Gefitinib (C) every other day
for 1 week starting from day 5.
(D–G) 1 3 104 B16-F10 cells were injected s.c.
into WT C57BL/6 or AREG/ (D and F) mice or
Egfrflox/flox3Cd4-cremice (E andG). On day 5 and
7 after tumor cell transfer, mice were immunized
with BM-DCs loaded with an immunogenic B16
melanoma epitope (TRP2180-188) (F and G) or left
unimmunized (D and E). Tumor size was deter-
mined on days 21 until 23 after tumor transfer. n =
3–7 mice per group; bars represent mean + SEM.
Immunity
Immune Regulatory Effect of EGFR Signalingdevelopment of dermatitis of WT C57BL/6 BM-chimeric mice
that had received Areg/ BM (Figure S1B).
These data obtained in mast cell-reconstituted mice indicate
that leukocyte-, in this case mast cell-derived, AREG can be of
crucial importance for efficient Treg cell functioning in vivo.
DISCUSSION
The pivotal role of Treg cells in immune regulation, i.e., in fine
tuning protective immune responses and minimizing harmful
pathology, has become widely appreciated. Despite this appre-
ciation, many aspects of the highly complex process of how Treg
cells are activated and, upon entry of inflamed tissues, are regu-
lated, remain incompletely understood. Different factors and cell
types have been shown to play a prominent role in this process,
and a number of factors have been identified that influence the
functionality of Treg cells at the site of inflammation. So far,
mainly factors that diminish Treg cell function, such as IL-6 or
TLR-mediated signals, have been described. Importantly,
however, experiments have demonstrated that Treg cells gain
optimal suppressive capacity only by migrating through the
site of inflammation (Zhang et al., 2009). This finding suggests
that at the site of inflammation also factors that enhance Treg
cell function must be present. In line with this thought, we here
demonstrate that AREG-induced and Treg cell-expressed
EGFR-mediated signals are of pivotal importance for the optimal280 Immunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc.functioning of Treg cells in vivo. In partic-
ular, the observations that AREG is the
single most upregulated growth factor
upon activation of human mast cells
(Wang et al., 2005) and that mast cell-
derived AREG can be of critical impor-
tance for optimal Treg cell function sheda new light on the interaction between mast cells and Treg
cells. Both Treg cells and mast cells rapidly infiltrate sites of
inflammation and mutual regulation has repeatedly been
described (reviewed in Mekori and Hershko, 2012). So far,
however, mainly factors such as the cytokines IL-9 (Lu et al.,
2006) and IL-2 (Hershko et al., 2011) have been described to
be involved in this cross talk between mast cells and Treg cells.
The main function of these cytokines, however, is to support
survival and proliferation of mast cells (Townsend et al., 2000)
and Treg cells (Burchill et al., 2007), respectively. Thus, interfer-
ence with either of these factors has strong influences on the
overall number of either type of cells. The finding presented
here, that mast cell-derived AREG can directly enhance Treg
cell function, adds a qualitative component to this interaction.
In the situation of developing tumors, both mast cells and Treg
cells are known to accumulate in the peritumoral region (Ju et al.,
2009) and we found that a particularly high percentage of Treg
cells in the ectopic lymphoid structures at the periphery of
tumors expressed the EGFR. Accumulation of mast cells around
tumors has repeatedly been associated with poor prognosis for
patients suffering from a number of tumors such as prostate
cancer (Johansson et al., 2010), melanoma (Ribatti et al.,
2003), breast cancer (Amini et al., 2007), or colon carcinoma
(Lachter et al., 1995). Mast cells have been shown to support
tumor growth in a number of different ways, for example, by
enhancing the vascularization of the tumor, in particular in the
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Figure 6. Mast Cell-Derived AREG Enhances Treg Cell Function
In Vivo
(A and B) 1 3 104 B16-F10 cells were injected s.c. into c-kitw-sh/w-sh mice re-
constituted with BM-MCs differentiated from BM derived fromWT C57BL/6 or
Areg/ mice or were left unreconstituted. On day 5 and 7 after tumor cell
transfer, micewere immunizedwith BM-DCs loadedwith an immunogenic B16
melanoma epitope (TRP2180-188) (A) or left unimmunized (B). Tumor size was
determined 23 days after tumor transfer. n = 5–7 mice per group. Bars
represent means + SEM.
(C) c-kitw-sh/w-sh mice were reconstituted with either WT or Areg/ BM-MCs.
Three weeks after reconstitution, 10,000 B16-F10 cells were injected. 21 days
after tumor cell transfer, tumors were harvested and stained for mast cells via
Csaba staining.
(D and E) c-kitw-sh/w-shRag1/mice were reconstituted with BM-MCs derived
from either WT C57BL/6 or Areg/mice or were left unreconstituted. 200,000
FoxP3/GFP CD4+ T cells were cotransferred with 400,000 naive CD4+ T cells
and colitis scores were determined 6 weeks after transfer. n = 3–7 mice per
group. Bars represent means + SEM.
For additional information, see Figure S6.
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Nevertheless, a contribution of mast cells to the tumor-intrinsic
immune-suppressive environment is well established as
well (Huang et al., 2008). Our data described here, that in
particular mast cell-derived AREG substantially contributes
to the immune-suppressive environment within tumors, suggest
a molecular mechanism by which mast cells may support
this Treg cell-mediated tumor-intrinsic immunosuppressive
environment.
In line with this hypothesis, it is tempting to speculate that the
immune-regulatory function of the EGFR may contribute to the
clinical successes of EGFR-targeting medications. Tumor treat-
ments often have multiple, sequential effects. Starting with the
direct killing of a portion of the tumor cells, the thereby released
tumor antigens can prime antitumor immune responses de novo
or reactivate dormant, anergic responses (Apetoh et al., 2007).
Our findings suggest that EGFR-targeting treatments may, in
addition, also allow treatment-induced antitumor immune
responses to be more effective, because the treatment may
also interfere with the suppressive capacity of tumor-intrinsic
Treg cells that otherwise could dampen the induced antitumor
immune response.
Our findings may explain also why EGFR-targeting treatments
in some tumors, such as colorectal carcinoma (Cunningham
et al., 2004), function primarily as an adjuvant to concomitant
chemotherapy (CT). CT induces cell death that results in release
of tumor antigens that can prime or reactivate antitumor T cell
responses and diminishes the overall tumor load temporarily
and, thus, the therewith associated immune-suppressive envi-
ronment (Zitvogel et al., 2008). More importantly, CT also
induces a transient lymphopenia in which dormant and/or aner-
gic tumor-specific T cell responses can be reactivated (Schie-
tinger et al., 2012). Thus, in patients undergoing CT treatment,
a similar situation is created as in our T cell transfer-induced
colitis model in Rag1/ mice. Most interestingly, also in many
other settings the enhancing effects of transient lymphopenia
on the induction of autoimmune responses have been observed
(Krupica et al., 2006; Guerau-de-Arellano et al., 2009) and in
particular in such lymphopenic situations, optimal Treg cell func-
tion has been shown to be of pivotal importance for maintenance
of immune tolerance and tissue homeostasis (Le Campion et al.,
2009). Thus, it is easy to envision that blocking of the EGFR on
Treg cells in combination with CT can enhance the efficacy
of tumor treatments—which closely correlates with what is
observed in the clinic (Cunningham et al., 2004). The exact
mechanisms by which EGFR-targeted treatments mediate their
objective clinical responses in cancer patients has remained
poorly understood and further targeted research to determine
the precise role of the immune system in the clinical successes
of EGFR-targeted tumor treatments is needed. Nevertheless,
our data showing a direct effect of the EGFR on Treg cell regula-
tion may reveal one unexpected effect of such treatments. A
much wider usage of EGFR-targeting treatments to enhance
antitumor immune responses concomitant to other tumor treat-
ments may therefore appear warranted.
Thus, taken together, we here reveal an EGFR-mediated
mechanism that contributes to the regulation of local immune
responses. Although factors that diminish Treg cell function at
the site of inflammation have been known for many years, weImmunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc. 281
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immune regulation probably will follow from the balance
between the two types of factors. It is easy to envision that either
type of factor could have a distinct relevance at different time
points of inflammation. During the acute phase, factors that
diminish Treg cell function most probably prevail, but when the
inflammation has cooled down, mast cell-derived AREG could
play a more prominent role and thereby prevent excessive tissue
damage and the development of chronic inflammations.
EXPERIMENTAL PROCEDURES
Mice
c-kitw-sh/w-sh and FoxP3-GFP transgenic mice were purchased from Jackson
Laboratory, CD4-cre mice were purchased from Taconics, and Egfrflox/flox
mice (Natarajan et al., 2007) were provided by M. Sibilia (University of Vienna).
Areg/, which had been backcrossed for at least 14 times onto a C57BL/6
background, B6.SJL (CD45.1), and Rag1/mice were bred in house under
specific-pathogen-free conditions. Mice were used between 7 and 17 weeks
of age. All animal experiments were approved by the Committee on Animal
Experiments of the University of Utrecht.
Nanobody Isolation
Because EGFR-blocking antibodies target the human EGFR only and do not
cross-react with the murine EGFR, we first screened antibodies derived
from llama immunoglobulin libraries for their capacity to interact with mouse
EGFR. Besides conventional immunoglobulins, llamas express single-domain,
heavy chain antibodies devoid of the light chain, known as nanobodies. We
isolated three nanobody-producing clones that targeted a stretch of the
EGFR that is conserved between mouse and human (Figure S6). To enhance
the nanobody half-life in the serum of treatedmice, a bivalent, bispecific nano-
body construct was prepared by cloning an anti-mouse albumin nanobody at
the C terminus of RR359, separated by a 15(G4S) linker; resulting in a serum
half-life of this bi-head nanobody of approximately 48 hr (data not shown).
Bivalent RR359 was expressed in S. cerevisiae shake flask cultures and puri-
fied via C-His tag affinity with 1 ml HisTrap column. For FACS staining, the
nanobody was dialyzed to PBS with 5 ml HiTrap Desalting column (both GE
Healthcare) and biotinylated with biotin (amido hexanoic acid 3-sulpho-N-
hydroxy succinimide ester, Roche); staining was performed in the presence
of Fc-block and/or unspecific, unlabeled nanobodies.
B16 Melanoma Vaccination
10,000 B16-F10 melanoma cells were transferred subcutaneously into the
lower left flank of mice. Mice were then either immunized with TRP2180-188
peptide-loaded BM-DCs on day 5 and 7 after transfer or left untreated. On
day 6 after tumor transfer, mice were i.p. injected every other day either with
10 mg/kg bodyweight Gefitinib or with 300 mg purified EGFR-blocking nano-
bodies. Assuming a half-life of about 48 hr, the level of nanobodies per mouse
was kept above 100 mg for 1week. A control group received once on day 5 after
transfer an i.p. injection of 50mg/kg bodyweight cyclophosphamide dissolved
in 100 ml PBS to inactivate Treg cells. 21 days after injection the tumor size was
determined. Up to a diameter of approximately 0.8 cm, tumors normally grew
perfectly round. At bigger sizes, space restrainments formed more oval-
shaped tumors; of these the average of width versus length was calculated.
Induced Colitis Mouse Model
Rag1/micewere injected with 43 105CD4+CD45RBhi cells to induce colitis.
If not stated differently in the figure legend, 2 3 105 Treg cells isolated from
Foxp3-GFP mice were cotransferred and 6 weeks later the mice were sacri-
ficed and colons scored by two independent experts in a blinded fashion
according to Berg et al. (1996). Scoring was as follows, in brief: grade 0, no
infiltration of mononuclear cells; grade 1, few foci of mononuclear cells, only
slight depletion of goblet cells; grade 2, many foci of mononuclear cells, infil-
tration in the lamina propria, but not yet in the submucosa; and diminished
numbers of goblet cells; grade 3, strong infiltration, also in the submucosa;
epithelial hyperplasia; and number of goblet cells strongly diminished; grade282 Immunity 38, 275–284, February 21, 2013 ª2013 Elsevier Inc.4, transmural infiltration of mononucleated cells; strong epithelial hyperplasia;
and goblet cell depletion. Overall histological score per mouse is the sum of
individual scores for the different segments of the colon (c. ascendens, c.
transversum, c. descendens).
Differentiation and Reconstitution of Bone Marrow-Derived Mast
Cells
Bone marrow-derived mast cells (BM-MCs) were differentiated in vitro from
bonemarrow cells that were cultured for 3 weeks in the presence of pokeweed
mitogen-stimulated spleen cell-conditioned medium as a source for IL-3.
Nonadherent cells were passed once a week into new medium and purity of
BM-MC population was determined by flow cytometry. Cultures contained
a uniform cell population to more than 94% positive for c-Kit and FcεRIa.
Mast cell-deficient c-kitw-sh/w-sh mice with an age of at least 8 weeks were
i.v. injected and received 5 3 106 cultured BM-MCs 3 weeks prior to start of
the experiments. Mast cell reconstitution of the inflamed area was determined
by Csaba staining and toluidine blue.
In Vitro Suppression Assay
Human
CD4+CD25hiCD127lo T cells isolated from human PBMCs were cocultured
with PBMCs labeled with 2 mM CFSE in anti-CD3 (clone OKT3)-coated
96-well plates. Cells were cultured for 4 days in RPMI medium supplemented
with 10% FCS, penicillin and streptomycin, and 2-mercaptoethanol, in the
presence or absence of 100 ng/ml recombinant Amphiregulin, purified from
the supernatant of COS7 cells that had been transiently transfected with
AREG-expressing vectors or purchased from R&D Systems. Proliferation of
CD4+ and CD8+ cells was determined by measuring CFSE dilution with the
FACS CANTO (BD Biosciences). Proliferation was defined as the percentage
of cells that have undergone at least one division.
Mouse
FACS-sorted Treg cells were added to CFSE-labeled CD45.1-expressing
splenocytes at different ratios. Cells were cultured in IMDM supplemented
with 10% FCS, glutamax, penicillin and streptomycin, and 2-mercaptoethanol
for 4 days, in the presence or absence of 100 ng/ml recombinant AREG. T cells
were activated with different amounts of soluble anti-CD3 (clone 145-2C11;
BD PharMingen). To determine suppression of proliferation, CFSE dilution
within the CD45.1-expressing T cell populations was analyzed by FACS. Prolif-
eration was defined as the percentage of cells that have undergone at least
one division.
Statistics
We performed data analysis with statistical software (Prizm 4.0, GraphPad
Software). Comparisons between two groups were performed with two-tailed
Mann-Whitney test. p values <0.05 were considered significant.
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